AUTHORS
Ying Wang, MD, PhD, Suning Chen2, Yuhua Li, MD, PhD3, Rui Huang4, Mingyuan Sun, MD5, Yan Li6, Xudong Wei, MD, PhD7, Ruihua Mi, MD, PhD8, He Huang, MD, PhD9, Yi Luo10, Xiaoyu Zhu, MD11, Jinhai Ren, MD12, Dengju Li, MD13, Fei Li, MD, PhD14, Bei Liu, PhD15, Wenting Hu, MD16, Xiaofan Zhu, MD17, Jun Luo18, Zhenfang Liu, DO19, Ying Zhang20, Prapti Patel21, Adrien Tessier22, Ang Li23, Depei Wu Sr, MD24
AFFILIATIONS
1 The First Affiliated Hospital of Soochow University, Suzhou, China
2 The First Affiliated Hospital of Soochow University, Suzhou, China
3 Zhujiang Hospital, Southern Medical University, Guangzhou, China
4 Zhujiang Hospital, Southern Medical University, Guangzhou, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7 Henan Cancer Hospital, Zhengzhou, China
8 Henan Cancer Hospital, Zhengzhou, China
9 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
10 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
11 Anhui Provincial Hospital, Hefei, China
12 The Second Hospital of Hebei Medical University, Shijiazhuang, China
13 Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China
14 The First Affiliated Hospital of Nanchang University, Nanchang, China
15 The First Hospital of Lanzhou University, Lanzhou, China
16 Shanghai Children’s Medical Center, Shanghai, China
17 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
18 The First Affiliated Hospital of Guangxi Medical University, Nanning, China
19 The First Affiliated Hospital of Guangxi Medical University, Nanning, China
20 Servier Pharmaceuticals, Shanghai, China
21 Servier Pharmaceuticals, Boston, MA, United States
22 Institut Servier de Médecine Translationnelle, Gif-sur-Yvette, France
23 Servier (Beijing) Pharmaceutical R&D Co., Ltd, Beijing, China
24 The First Affiliated Hospital of Soochow University, Suzhou, China
ABSTRACT
Background: Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are associated with poor clinical outcomes and limited treatment (Tx) options following relapse or Tx failure. Advances in acute leukemia care include the development of menin inhibitors, which target menin-driven proliferative mechanisms associated with KMT2A or NUP98 rearrangements (KMT2Ar and NUP98r) or NPM1 mutations (NPM1m). While menin inhibitors have shown clinical activity, responses are not universal and acquired resistance may limit response durability. Effective Tx options remain an unmet need. Early data suggest that BN104 (proposed non-proprietary name: vicrimenib) has a favorable preclinical profile and represents a promising frontline option among existing menin inhibitors. We report Phase 1/2 safety, tolerability, and efficacy of vicrimenib in pts with R/R acute leukemia harboring KMT2Ar, NPM1m, or NUP98r to establish a recommended Phase 2 dose.
Methods: This ongoing, multicenter, open-label, Phase 1/2, first-in-human study (NCT06052813) was conducted across 12 sites in China (October 19, 2023–March 20, 2026). Eligible pts were aged ≥12 years with R/R AML/ALL, per WHO criteria (2022), harboring KMT2Ar, NPM1m, or NUP98r. The required weight of adolescent pts (aged ≥12 to <18 years) was ≥40 kg. A 3+3 dose escalation was used to evaluate oral vicrimenib at doses 200 mg QD, 200 mg BID, 400 mg BID, and 600 mg BID administered in continuous 28-day cycles. Following dose escalation, pts were randomized 1:1 to preselected 400 mg BID and 600 mg BID groups and stratified by mutation status during dose optimization. Primary objectives were to evaluate safety and tolerability of vicrimenib by assessing incidence of dose-limiting toxicities (DLTs) and serious adverse events (SAEs). Preliminary efficacy endpoints included OS, CR, CR/CRh, ORR, DOR, and MRD-negative remission. Analyses were descriptive. Due to limited pt numbers, NUP98r was excluded from the efficacy analysis population; separate statistical analysis was not performed.
Results: A total of 70 pts were enrolled and received ≥1 dose of vicrimenib (safety population), with 66 adult and 4 adolescent pts; 61 pts were evaluable for efficacy (pts without KMT2Ar and NPM1m [n=9] were excluded). Median age was 44.0 years (range 13–82) and mostly comprised pts with AML (95.7% [67/70]); 68.6% (48/70) had KMT2Ar, 20.0% (14/70) had NPM1m, and 7.1% (5/70) had NUP98r. Median number of previous Tx lines was 2.0 (range 1–8) and 81.4% (57/70) of pts received prior venetoclax. No DLTs were reported; almost all pts (98.6% [69/70]) experienced ≥1 Tx-emergent adverse event. SAEs occurred in 58.6% (41/70) of pts, with similar incidence in the 400 mg BID (59.5% [22/37]) and 600 mg BID (55.2% [16/29]) groups. The most frequent SAEs were decreased platelet count in 22.9% (16/70) and pneumonia in 18.6% (13/70) of pts. QT interval prolongation and differentiation syndrome adverse events were reported in 14.3% (10/70) and 12.9% (9/70) of pts, respectively. In the efficacy population, median follow-up time was 11.5 months (range 0.3–24.0). Median OS was 16.7 months (95% confidence interval [CI] 10.0–not reached [NR]). CR was achieved in 32.8% (20/61), CR/CRh in 54.1% (33/61), and ORR was 82.0% (50/61). Median DOR in the 50 pts with an objective response was 7.5 months (95% CI 4.6–NR); by dose: 7.8 months (95% CI 2.1–NR) in the 400 mg BID group and 7.5 months (95% CI 4.4–NR) in the 600 mg BID group. Of pts with KMT2Ar (400 mg BID), CR and CR/CRh was 28.0% (7/25), 48.0% (12/25), respectively; ORR was 76.0% (19/25). With 600 mg BID, CR and CR/CRh were greater vs 400 mg BID: 45.0% (9/20) and 70.0% (14/20), respectively; ORR was 95.0% (19/20). Of pts with KMT2Ar who achieved CR, 94.1% (16/17) were MRD-negative. Of 14 pts with NPM1m (including 400 mg BID and 600 mg BID dose groups), 28.6% (4/14) achieved CR and 42.9% (6/14) achieved CR/CRh; ORR was 78.6% (11/14). Of the 4 pts who achieved CR, all were MRD-negative. Of 5 pts with NUP98r, 20.0% (1/5) achieved CR.
Conclusion: Vicrimenib demonstrated an acceptable safety profile, with promising efficacy and durability, in a population with R/R acute leukemia harboring KMT2Ar, NPM1m or NUP98r. Between 400 mg BID and 600 mg BID groups, comparable tolerability and numerically higher response rates in KMT2Ar support 600 mg BID for evaluation in the ongoing, second part of this study. A global Phase 1b/2 study of vicrimenib monotherapy in R/R acute leukemia is planned.
DISCLOSURES
Ying Wang, MD, PhD: No relevant conflicts of interest to declare.